Home
My Account
About Us
Forum
Contact us
الواجهة العربية
epharmaweb.com
Medical News Medical News
Aricles Articles
Events Events
Guidelines Guidelines
Videos Library Videos Library
Diseases Diseases
Follow us : facebook twitter Digg Linkedin Boxiz
Newsletter

Please select the categories you are intersted in:
News Articles Guidelines Events Videos Journals' abstracts

Latest Subscribers
Advanced Search »



Effect of daily aspirin on risk of cancer metastasis



Effect of daily aspirin on risk of cancer metastasis

Prof Peter M Rothwell, Michelle Wilson, Jacqueline F Price, Prof Jill FF Belch, Prof Tom W Meade, Ziyah Mehta

The Lancet,
379:9826, March 21, 2012

Effect of daily aspirin on risk of cancer metastasis

Background
Daily aspirin reduces the long-term incidence of some adenocarcinomas, but effects on mortality due to some cancers appear after only a few years, suggesting that it might also reduce growth or metastasis. We established the frequency of distant metastasis in patients who developed cancer during trials of daily aspirin versus control.

 


Methods
Our analysis included all five large randomised trials of daily aspirin (≥75 mg daily) versus control for the prevention of vascular events in the UK. Electronic and paper records were reviewed for all patients with incident cancer. The effect of aspirin on risk of metastases at presentation or on subsequent follow-up (including post-trial follow-up of in-trial cancers) was stratified by tumour histology (adenocarcinoma vs other) and clinical characteristics.

 


Findings
Of 17 285 trial participants, 987 had a new solid cancer diagnosed during mean in-trial follow-up of 6•5 years (SD 2•0). Allocation to aspirin reduced risk of cancer with distant metastasis (all cancers, hazard ratio [HR] 0•64, 95% CI 0•48—0•84, p=0•001; adenocarcinoma, HR 0•54, 95% CI 0•38—0•77, p=0•0007; other solid cancers, HR 0•82, 95% CI 0•53—1•28, p=0•39), due mainly to a reduction in proportion of adenocarcinomas that had metastatic versus local disease (odds ratio 0•52, 95% CI 0•35—0•75, p=0•0006). Aspirin reduced risk of adenocarcinoma with metastasis at initial diagnosis (HR 0•69, 95% CI 0•50—0•95, p=0•02) and risk of metastasis on subsequent follow-up in patients without metastasis initially (HR 0•45, 95% CI 0•28—0•72, p=0•0009), particularly in patients with colorectal cancer (HR 0•26, 95% CI 0•11—0•57, p=0•0008) and in patients who remained on trial treatment up to or after diagnosis (HR 0•31, 95% CI 0•15—0•62, p=0•0009). Allocation to aspirin reduced death due to cancer in patients who developed adenocarcinoma, particularly in those without metastasis at diagnosis (HR 0•50, 95% CI 0•34—0•74, p=0•0006). Consequently, aspirin reduced the overall risk of fatal adenocarcinoma in the trial populations (HR 0•65, 95% CI 0•53—0•82, p=0•0002), but not the risk of other fatal cancers (HR 1•06, 95% CI 0•84—1•32, p=0•64; difference, p=0•003). Effects were independent of age and sex, but absolute benefit was greatest in smokers. A low-dose, slow-release formulation of aspirin designed to inhibit platelets but to have little systemic bioavailability was as effective as higher doses.

 


Interpretation
That aspirin prevents distant metastasis could account for the early reduction in cancer deaths in trials of daily aspirin versus control. This finding suggests that aspirin might help in treatment of some cancers and provides proof of principle for pharmacological intervention specifically to prevent distant metastasis.







اضغط هنا للقراءة باللغة العربية

Prepared by: Houssam Nahhas






Forgot your password


sign up

Consultants Corner

Yaser Habrawi , F.R.C.S.Ed

Yaser Habrawi , F.R.C.S.Ed Consultant Ophthalmologist

Samir Moussa M.D.

Samir Moussa M.D. ENT Specialist

Dr . Dirar Abboud

Dr . Dirar Abboud Hepatologist – Gastroenterologist

Dr. Talal Sabouni

Dr. Talal Sabouni UROLOGY AND KIDNEY TRANSPLANT

Dr. Tahsin Martini

Dr. Tahsin Martini Degree status: M.D. in Ophthalmology

Dr. Hani Najjar

Dr. Hani Najjar Pediatrics, Neurology

Dr. Samer Al-Jneidy

Dr. Samer Al-Jneidy Pediatrician

Dr. Faisal Dibsi

Dr. Faisal Dibsi Specialist of Otolaryngology - Head and Neck Surgery
Poll

Which of the following you are mostly interested in?

Cancer Research
Mental Health
Heart Disease & Diabetes
Sexual Health
Obesity and Healthy Diets
Mother & Child Health

Disclaimer : This site does not endorse or recommend any medical treatment, pharmaceuticals or brand names. More Details